Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

From the PhD to Equity Research Analyst

Interested in translating your science critical thinking skills to the market? Listen to Caroline Corner describe how she left the lab bench to break into the finance industry as an equity research analyst and consultant.

Published November 15, 2012

Caroline V. Corner, PhD
Consultant, Optio Biopharma Consulting

Caroline Corner, PhD, has been an equity research analyst since 2005, when she became a member of Wells Fargo Securities research team covering medical technology companies. Since leaving Wells Fargo, Caroline has been a Senior Equity Research Analyst at MLV & Company, Pacific Growth Equities, and Montgomery & Company, covering the medical device and diagnostics sectors, as well as regenerative medicine companies. Dr. Corner is currently working as a consultant, with clients in investment banking and academia. Prior to entering equity research, she held engineering and product development positions at Baxter Transfusion Therapies and Eli Lilly and Company. Caroline has a PhD in Biological and Environmental Engineering from Cornell University, where she also did graduate course work at the Johnson School of Business, and a BS in Biological Systems Engineering from Virginia Tech. Caroline is based in San Francisco.

From the PhD to Equity Research Analyst

Caroline V. Corner (Optio Biopharma Consulting)